These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 19419595

  • 1. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG, Weiden PJ, Loebel AD, Warrington LE, Watsky EJ, Siu CO.
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [Abstract] [Full Text] [Related]

  • 2. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM, Malla A, Newcomer JW, Potkin SG, Weiden PJ, Harvey PD, Loebel A, Watsky E, Siu CO, Romano S.
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [Abstract] [Full Text] [Related]

  • 3. Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol.
    Harvey PD, Pappadopulos E, Lombardo I, Kremer CM.
    Schizophr Res; 2009 Nov; 115(1):24-9. PubMed ID: 19189878
    [Abstract] [Full Text] [Related]

  • 4. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP, Spina E, Murray S, Yang R.
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [Abstract] [Full Text] [Related]

  • 5. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
    Hirsch SR, Kissling W, Bäuml J, Power A, O'Connor R.
    J Clin Psychiatry; 2002 Jun; 63(6):516-23. PubMed ID: 12088164
    [Abstract] [Full Text] [Related]

  • 6. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study.
    Vieta E, Ramey T, Keller D, English PA, Loebel AD, Miceli J.
    J Psychopharmacol; 2010 Apr; 24(4):547-58. PubMed ID: 19074536
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE, Pantelis C, Dineen M, Benattia I, Romano SJ.
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [Abstract] [Full Text] [Related]

  • 8. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM, Glick ID, Weiden PJ, Romano SJ, Siu CO.
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L, Meng X, Hochfeld M, Stahl SM.
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [Abstract] [Full Text] [Related]

  • 10. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L, INITIATE Study Group.
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [Abstract] [Full Text] [Related]

  • 11. Augmentation of clozapine with ziprasidone in refractory schizophrenia: a double-blind, placebo-controlled study.
    Muscatello MR, Pandolfo G, Micò U, Lamberti Castronuovo E, Abenavoli E, Scimeca G, Spina E, Zoccali R, Bruno A.
    J Clin Psychopharmacol; 2014 Feb; 34(1):129-33. PubMed ID: 24145221
    [Abstract] [Full Text] [Related]

  • 12. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study.
    Brook S, Walden J, Benattia I, Siu CO, Romano SJ.
    Psychopharmacology (Berl); 2005 Apr; 178(4):514-23. PubMed ID: 15650846
    [Abstract] [Full Text] [Related]

  • 13. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, Walker DJ, Roychowdhury SM, Kane JM.
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, El Tallawy H, Danaci AE, Lowe W, Karayal ON.
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [Abstract] [Full Text] [Related]

  • 15. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano RJ, O'Gorman C, Harrigan RH.
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [Abstract] [Full Text] [Related]

  • 16. Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study.
    Schennach R, Riedel M, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ.
    Pharmacopsychiatry; 2019 Jul; 52(4):180-185. PubMed ID: 30235496
    [Abstract] [Full Text] [Related]

  • 17. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder.
    Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN.
    J Clin Psychopharmacol; 1998 Aug; 18(4):296-304. PubMed ID: 9690695
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Ratner Y, Gibel A, Yorkov V, Ritsner MS.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct 01; 31(7):1401-9. PubMed ID: 17669574
    [Abstract] [Full Text] [Related]

  • 19. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G, Trixler M, Bitter I, Degrell I, Füredi J, Faludi G, Ziprasidonra Váltást Vizsgáló Munkacsoport.
    Neuropsychopharmacol Hung; 2006 Dec 01; 8(4):201-9. PubMed ID: 17211055
    [Abstract] [Full Text] [Related]

  • 20. Ziprasidone in Black patients with schizophrenia: analysis of four short-term, double-blind studies.
    Lawson WB, Herman BK, Loebel A, Lazariciu I, Malik M.
    CNS Spectr; 2009 Sep 01; 14(9):478-86. PubMed ID: 19890230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.